CVS/Aetna To Merge In Defensive Play To Reshape Healthcare Delivery

The pharmacy retail chain and drug distributor will buy the insurer for $69bn in a merger to build what the companies say will be a new, more affordable healthcare concept.

Female CVS retail pharmacist with patient

The pharmacy retail giant CVS Health Corp.'s purchase of health insurer Aetna Inc. in a $69bn merger will shake up the way drugs and healthcare are delivered. The companies say a more integrated healthcare management and delivery platform will help eliminate waste and make healthcare more affordable, while also presenting new opportunities through CVS' walk-in clinics to bring expanding healthcare options to patients.

The combination of two heavyweights working in different areas of the healthcare spectrum could present speed bumps in the near-term, but the move announced Dec

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Supply Chain

Pharma Predicts Modest Impact From Tariffs, But It Depends On What Comes Next

 

Drugmakers aren’t expecting a big financial hit from tariffs for now, but a report commissioned by PhRMA suggests the cost of pharma-sector tariffs could be steep.

Transient FY26 For Syngene But Momentum In China +1 Projects

 

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

 
• By 

Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.

Soriot Cautions Europe Amid More US Expansion

 
• By 

The AstraZeneca CEO again calls for rich European countries to pay more for new drugs because "a model where the US funds innovation in our industry for the entire world doesn't work."

More from Business

Switzerland Biopharma To Stay Strong Despite More Cash Going To US And China

 
• By 

The sector is continuing to show resilience despite financial and market challenges.

Deal Watch: Lilly Looks To Creyon For Oligonucleotides

 
• By 

Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

 

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.